Keywords: Forest Labs, TransTech Pharma, Glucokinase activators, Diabetes

Forest Labs has another stab at diabetes drug licensing in deal worth potential $1 billion to TransTech Pharma for glucokinase activators

Article | 09 June 2010

US drugmaker Forest Laboratories has entered into a license agreement for the development and commercialization of small-molecule compounds discovered and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Forest Laboratories

TransTech Pharma

Go to company listing